Article
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine response.
Alimentary pharmacology & therapeutics - 1 May 2010
Rotman Y, Borg B B, Soza A, Feld J J, Modi A A, Loomba R, Lutchman G, Rivera E, Doo E, Ghany M G, Heller T, Neumann A U, Liang T J, Hoofnagle J H
Abstract excerpt
BACKGROUND: Chronic infection with hepatitis C, genotype 2/3, responds better than other genotypes to peginterferon and ribavirin treatment. We hypothesized that a lower dose of peginterferon would be as effective, but less toxic than standard doses. AIM: To test the hypothesis that a lower dose of peginterferon would be as effective as, but less toxic than, standard doses. METHODS: A total of 30 patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.